23 results match your criteria: "and Baker Heart and Diabetes Institute[Affiliation]"
Eur Heart J
December 2024
School of Biomedical Engineering & Imaging Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, UK.
Heart Lung Circ
November 2024
Centre for Heart Rhythm Disorders, The University of Adelaide; South Australian Health and Medical Research Institute; and Royal Adelaide Hospital, Adelaide, SA, Australia. Electronic address:
Atrial fibrillation (AF) is highly prevalent in the Australian community, ranking amongst the highest globally. The consequences of AF are significant. Stroke, dementia and heart failure risk are increased substantially, hospitalisations are amongst the highest for all cardiovascular causes, and Australians living with AF suffer from substantial symptoms that impact quality of life.
View Article and Find Full Text PDFPharmacol Rev
October 2024
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (S.B.R., Y.X., M.A., S.H., L.H., O.M.F., G.G., A.A., Z.L., M.A.F., I.K.S., C.J.H.P., E.C., N.L.T.); China Pharmaceutical University, Nanjing, China (S.H., L.H.); Applied Surgery and Metabolism Laboratory, School of Biological Sciences (A.R.J.P.) and Surgical and Translational Research Centre, Department of Surgery, Faculty of Medical and Health Sciences (A.R.J.P., J.A.W.), University of Auckland, Auckland, New Zealand; and Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (N.L.T.).
Historically, the intestinal lymphatics were considered passive conduits for fluids, immune cells, dietary lipids, lipid soluble vitamins, and lipophilic drugs. Studies of intestinal lymphatic drug delivery in the late 20th century focused primarily on the drugs' physicochemical properties, especially high lipophilicity, that resulted in intestinal lymphatic transport. More recent discoveries have changed our traditional view by demonstrating that the lymphatics are active, plastic, and tissue-specific players in a range of biological and pathological processes, including within the intestine.
View Article and Find Full Text PDFDiabetes Care
August 2024
Department of Public Health and Implementation Science, La Trobe University, and Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Despite extensive evidence related to the prevention and management of type 2 diabetes (T2D) and its complications, most people at risk for and people who have diabetes do not receive recommended guideline-based care. Clinical implementation of proven care strategies is of the utmost importance because without this, even the most impressive research findings will remain of purely academic interest. In this review, we discuss the promise and challenges of implementing effective approaches to diabetes prevention and care in the real-world setting.
View Article and Find Full Text PDFJ Rheumatol
May 2024
J.L. Fairley, MBBS, A. Burns, PhD, D. Prior, PhD, K. Morrisroe, PhD, M. Nikpour, PhD, L.J. Ross, PhD, The University of Melbourne, and St. Vincent's Hospital Melbourne.
Objective: To explore the effect of left ventricular (LV) diastolic dysfunction (LVDD) in systemic sclerosis (SSc)-associated interstitial lung disease (ILD), and to investigate SSc-specific associations and clinical correlates of LVDD.
Methods: There were 102 Australian Scleroderma Cohort Study participants with definite SSc and radiographic ILD included. Diastolic function was classified as normal, indeterminate, or abnormal according to 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging guidelines for assessment of LV diastolic function.
N Engl J Med
October 2023
The authors' affiliations are as follows: the Center for Population Health Innovation, University Heart and Vascular Center Hamburg (C.M., F.M.O., T.L., R.T., J.W., A.Z., S.B.), University Medical Center Hamburg-Eppendorf (C.M., F.M.O., T.L., R.T., J.W., A.Z., S.B.), the German Center for Cardiovascular Research (DZHK) Partner Site Hamburg-Kiel-Lübeck (C.M., T.L., R.T., J.W., S.B.), the Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, and Network Aging Research, Heidelberg University, Heidelberg (H.B., B.S.), the Department of Internal Medicine B, University Medicine Greifswald, and DZHK Partner Site Greifswald, Greifswald (M.D.), DZHK Partner Site Munich Heart Alliance (W.K., A. Peters), the German Heart Center, Technical University of Munich (W.K.), and the Institute for Medical Information Processing, Biometry, and Epidemiology, Medical Faculty, Ludwig Maximilians Universität München (A. Peters, B.T.), Munich, the Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm (W.K.), the Institute of Clinical Chemistry and Laboratory Medicine (K.J.L.), Preventive Cardiology and Preventive Medicine (P.S.W.), and Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (P.S.W.), University Medical Center of the Johannes Gutenberg-University Mainz, DZHK Partner Site Rhine-Main (K.J.L., P.S.W.), and Institute for Molecular Biology (P.S.W.), Mainz, the University Heart and Vascular Center Frankfurt, DZHK Partner Site Rhine-Main, Frankfurt (D.M.L.), the Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (A. Peters, B.T.), and German Center for Diabetes Research (DZD) Partner Site Munich-Neuherberg (A. Peters, B.T.), Neuherberg - all in Germany; the Department of Medicine (Cardiology), McMaster University, Hamilton, Canada (D.P.L.); the Experimental Medicine Research Unit, School of Medicine, National Autonomous University of Mexico, Mexico City (J.A.-D.), and Centro de Estudios en Diabetes, Centro de Investigacion en Salud Poblacional, Instituto Nacional de Salud Publica, Cuernavaca (C.G.) - both in Mexico; Université de Lille, INSERM, Centre Hospitalier University de Lille, Institut Pasteur de Lille, UMR1167-RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Epidemiology and Public Health Department, Lille (P.A.), the Department of Cardiology, INSERM UMR1295, Toulouse Rangueil University Hospital, Toulouse (J.F.), and the Department of Public Health, Strasbourg University Hospital, University of Strasbourg, Strasbourg (M.M.) - all in France; the Division of Clinical and Health Services Research, National Institute on Minority Health and Health Disparities (L.A.-S.), and the Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute (M.N.), National Institutes of Health, Bethesda, MD; the Department of Public Health and Primary Care, Ghent University, Ghent, Belgium (D.D.B.); the Department of Medicine, Baylor College of Medicine (C.M.B.), and Michael E. DeBakey Veterans Affairs Hospital and Baylor College of Medicine (V.N.), Houston, and the Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (J.L.) - all in Texas; the CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (A.B.-O., J.J.M.); the Department of Epidemiology and Public Health (M.B.) and the Research Department of Primary Care and Population Health (S.G.W.), University College London, London, the Centre for Public Health, Queens University Belfast, Belfast (F.K.), and the Cardiovascular Epidemiology Unit, Institute of Cardiovascular Research, University of Dundee, Dundee (H.T.-P.) - all in the United Kingdom; the Emory Global Diabetes Research Center and Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta (R.M.C.-L.); the School of Public Health, University of Queensland, Brisbane (A.D.), the Division of Cancer Epidemiology, Cancer Council Victoria (A.M.H.), the Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, the University of Melbourne (A.M.H.), and Baker Heart and Diabetes Institute (J.E.S.), Melbourne, the Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney (J.J.M.), and the George Institute for Global Health (A.E.S.), Sydney, and the School of Population Health (A.E.S.), University of New South Wales, Kensington (L.A.S.) - all in Australia; the Department of Cardiovascular and Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome (C.D., L.P.), the Research Center in Epidemiology and Preventive Medicine, Department of Medicine and Surgery, University of Insubria, Varese (M.M.F., L.I., G.V.), the Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli (G. de Gaetano, L.I.), Clinica Medica, University of Milano-Bicocca, Milan (G. Grassi), and the MONICA (Monitoring Cardiovascular Diseases)-Friuli Study Group, Udine (D.V.) - all in Italy; the Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, National Institute of Cardiology, and Lazarski University, Warsaw (W.D.), and the Department of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow (A. Pajak) - all in Poland; the Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen (R.P.D.), and the Departments of Neurology (M.K.I.) and Epidemiology (M.K.I., M.K.), Erasmus University Medical Center Rotterdam, Rotterdam - both in the Netherlands; the Department of Clinical Sciences Malmö, Lund University, Malmö (G.E., O.M.), the Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University (U.R.), and the Department of Medical Sciences, Uppsala University, Uppsala (L.L.), and the Department of Public Health and Clinical Medicine, University of Umea, Umea (S. Söderberg) - all in Sweden; the Department of Epidemiology, Tel Aviv University School of Public Health, Tel Aviv, Israel (U.G.); HUNT (Trøndelag Health Study) Research Center, Department of Public Health and Nursing, Norwegian University of Science and Technology, Levanger (K.H.), the K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Trondheim(K.H.), the Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog (M.N.L.), the K.G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo (M.N.L.), and the Department of Clinical Medicine, University of Tromsø the Arctic University of Norway, Tromsø (E.B.M.) - all in Norway; the Department of Chronic Diseases, Institute for Clinical Effectiveness and Health Policy, Buenos Aires (V.I.); Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul, Gambia (M.J., A.M.P.); the Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki (P.J., K.K., V.S.); Medical Research Council-Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda (P.K., J.M.); the Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences (D.K.), the Liver and Pancreaticobiliary Disease Research Center (R.M.), the Digestive Oncology Research Center (R.M., H.P.), and the Digestive Disease Research Center (R.M., M.N., H.P., S.G.S.), Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences - all in Tehran, Iran; the National Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Moscow (A.K.), and the Research Institute of Internal and Preventive Medicine-Branch of the Federal Research Center Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk (S.M.) - both in Russia; the Department of Clinical Medicine, Faculty of Health and Medical Sciences (A.L.), and the Department of Cardiology, Bispebjerg Hospital (E.P.), University of Copenhagen, and the Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital (A.L.) - both in Copenhagen; the Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia (A.M.); the Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka (T.N., S. Sakata), and the Global Center of Excellence Program Study Group, Yamagata University School of Medicine, Yamagata (M.W.) - both in Japan; the School of Medicine, University of Passo Fundo, Passo Fundo (K.O.), and the Department of Public Health, Postgraduate Program in Public Health, Federal University of Santa Catarina, Florianopolis (E.O.) - both in Brazil; the School of Health Sciences and Education, Harokopio University, Athens, Greece (D.P.); the National Council of Applied Economic Research, Delhi (A. Perianayagam), and the International Institute for Population Sciences, Mumbai (A. Perianayagam) - both in India; the Catalan Department of Health, Barcelona (S. Sans); the Hypertension in Africa Research Team, South African Medical Research Council Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom (A.E.S.), and the School of Mathematics, Statistics, and Computer Science, University of KwaZulu-Natal, Pietermaritzburg (A.Z.) - both in South Africa; the Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal (S.K.S.); the Laboratory of Population Studies, Institute of Cardiology, and the Department of Preventive Medicine, Faculty of Public Health, Lithuanian University of Health Sciences, Kaunas, Lithuania (A.T.); the China Center for Health Development Studies (Y.Y.) and Center for Healthy Aging and Development Studies, National School of Development (Y.Z.), Peking University, and the Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education (Y.Y.) - both in Beijing; the Center for the Study of Aging and Human Development and Geriatrics Division, Medical School of Duke University, Durham, NC (Y.Z.); and Cardio-CARE, Davos (A.Z., S.B.), and the Swiss Institute of Bioinformatics, Lausanne (A.Z.) - both in Switzerland.
Background: Five modifiable risk factors are associated with cardiovascular disease and death from any cause. Studies using individual-level data to evaluate the regional and sex-specific prevalence of the risk factors and their effect on these outcomes are lacking.
Methods: We pooled and harmonized individual-level data from 112 cohort studies conducted in 34 countries and 8 geographic regions participating in the Global Cardiovascular Risk Consortium.
Mol Cell Biochem
March 2023
The Alfred, and Baker Heart and Diabetes Institute, Melbourne, Australia.
Atrial fibrillation (AF) is an irregular heart rhythm, characterised by chaotic atrial activation, which is promoted by remodelling. Once initiated, AF can also propagate the progression of itself in the so-called ''AF begets AF''. Several lines of investigation have shown that signalling molecules, including reactive oxygen species, angiotensin II, and phosphoinositide 3-kinases (PI3Ks), in presence or absence of cardiovascular disease risk factors, stabilise and promote AF maintenance.
View Article and Find Full Text PDFLancet Glob Health
June 2022
Healthy Liveable Cities Lab, RMIT University, Melbourne, VIC, Australia; School of Population Health, The University of Western Australia, Perth, WA, Australia.
An essential characteristic of a healthy and sustainable city is a physically active population. Effective policies for healthy and sustainable cities require evidence-informed quantitative targets. We aimed to identify the minimum thresholds for urban design and transport features associated with two physical activity criteria: at least 80% probability of engaging in any walking for transport and WHO's target of at least 15% relative reduction in insufficient physical activity through walking.
View Article and Find Full Text PDFJ Am Coll Cardiol
May 2022
Cardiovascular Research Foundation, New York, New York, USA. Electronic address:
Intern Med J
December 2021
Division of Cardiology, Alfred Health, Melbourne, Victoria, Australia.
Congenital long QT syndrome (LQTS) is a familial cardiac ion channelopathy first described over 60 years ago. It is characterised by prolonged ventricular repolarisation (long QT on electrocardiography), ventricular arrhythmias and associated syncope or sudden cardiac death. As the most closely studied cardiac channelopathy, over the decades we have gained a deep appreciation of the complex genetic model of LQTS.
View Article and Find Full Text PDFJACC Clin Electrophysiol
March 2021
Division of Cardiology, University of California-San Francisco, San Francisco, California, USA. Electronic address:
Pharmacol Res
March 2021
The Alfred, and Baker Heart and Diabetes Institute, Melbourne, Australia; University of Melbourne, Melbourne, Australia.
Genetically modified animal studies have revealed specific expression patterns and unequivocal roles of class I PI3K isoenzymes. PI3K(p110α), a catalytic subunit of class I PI3Ks is ubiquitously expressed and is well characterised in the cardiovascular system. Given that genetic inhibition of PI3K(p110α) causes lethal phenotype embryonically, the catalytic subunit is critically important in housekeeping and biological processes.
View Article and Find Full Text PDFRural Remote Health
January 2020
Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT 0811, Australia; and Baker Heart and Diabetes Institute, PO Box 6492, Melbourne, Vic., Australia
Introduction: This study sought to determine change in chronic condition risk factors in a remote Indigenous community following a 3-year period of community-led health promotion initiatives.
Methods: Data were compared between two cross-sectional surveys of Indigenous Australian community residents before and after health promotion activities, and longitudinal analysis of participants present at both surveys using multilevel mixed-effects regression.
Results: At baseline, 294 (53% women; mean age 35 years) participated and 218 attended the second survey (56% women, mean age 40 years), and 87 attended both.
JACC Cardiovasc Imaging
April 2020
Department of Cardiology, The Alfred Hospital, and Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. Electronic address:
Am J Cardiol
December 2019
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
In patients with heart failure and preserved or mildly reduced ejection fractions (EF ≥40%), implantation of an interatrial shunt device (IASD) resulted in heterogenous changes of the left atrial (LA) volume. Baseline characteristics that correlate with a favorable decrease in LA volume are unknown. We hypothesized that a larger ratio of left to right atrial volume at baseline would correlate strongly with LA volume decongestion following IASD implantation.
View Article and Find Full Text PDFEur Heart J
August 2020
The Barts Heart Centre, Barts Health NHS Trust, Department of Arrhythmia Management, London, UK.
Hypertension
December 2019
From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.C.C., N.N.L., A.F.D., R.M.T., C.D.).
J Hypertens
August 2019
Sydney Medical School, University of Sydney and Baker Heart and Diabetes Institute, Sydney, New South Wales, Australia.
N Engl J Med
October 2018
From the Department of Epidemiology and Preventive Medicine, Monash University (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy Practice and Science, College of Pharmacy and Department of Family Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, National Institute on Aging, Bethesda, MD (B.R.).
Background: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo.
Methods: From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability.
J Cardiovasc Magn Reson
February 2018
Departments of Medicine and Diagnostic Radiology, McGill University, Montréal, Québec, Canada.
J CARDIOVASC MAGN RESON (2017) 19: 75. DOI: 10.1186/S12968-017-0389-8: In the original publication of this article [1] the "Competing interests" section was incorrect.
View Article and Find Full Text PDFCirculation
January 2018
Northwestern University Feinberg School of Medicine, Chicago, IL (M.J.R., S.J.S.)
Background: In nonrandomized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), fewer symptoms, and greater quality of life and exercise capacity in patients with heart failure (HF) and midrange or preserved ejection fraction (EF ≥40%). We conducted the first randomized sham-controlled trial to evaluate the IASD in HF with EF ≥40%.
Methods: REDUCE LAP-HF I (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) was a phase 2, randomized, parallel-group, blinded multicenter trial in patients with New York Heart Association class III or ambulatory class IV HF, EF ≥40%, exercise PCWP ≥25 mm Hg, and PCWP-right atrial pressure gradient ≥5 mm Hg.
Hypertension
June 2017
From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.).
Circ Cardiovasc Imaging
April 2017
From the Department of Cardiovascular Sciences, KU Leuven, Belgium (G.C., A.L.G.); Department of Cardiovascular Medicine, University Hospitals Leuven, Belgium (G.C.); and Baker Heart and Diabetes Institute, Melbourne, Australia (A.L.G.).